New antibody drug targets advanced cancers in Mid-Stage trial
Disease control
Recruiting now
This study tests a new drug, PRL3-zumab, in 52 adults with advanced solid tumors that have not responded well to prior treatments. The drug is given every two weeks by IV. The main goal is to see how long the cancer stays under control and whether the drug is safe. This is not a …
Phase: PHASE2, PHASE3 • Sponsor: Intra-IMMUSG Pte Ltd • Aim: Disease control
Last updated May 15, 2026 11:57 UTC